NEUCHATEL, Switzerland, August 5, 2010 /PRNewswire/ -- Elsevier Properties SA is pleased to congratulate Dr. Scott Stewart on his winning the Royal Australian Chemical Institute's (RACI) 2010/11 Athel Beckwith Lectureship, sponsored by Reaxys.
The award is open to all RACI members who have been appointed to their first academic or industrial position within the past five years. As the award winner, Dr. Stewart will be given the opportunity to present a lecture in at least six Australian state capitals and/or major regional centers during the year of the lectureship. The Organic Division of RACI established the annual lectureship to provide funding for outstanding early career organic chemists to travel around Australia and present the results of their research work.
Dr. Stewart, from the University of Western Australia, completed a PhD at the Research School of Chemistry (ANU) on the enantioselective synthesis of two new anti-cancer agents Taxol and Phomopsidin. His research interests include the synthesis of biologically active natural products using palladium catalysed cross coupling reactions; domino transformations in synthetic chemistry; medicinal chemistry for the treatment of cancer and immune diseases; and intramolecular Heck reactions using new nickel and palladium catalysts.
David Evans PhD, Scientific Affairs Director at Elsevier Properties SA said, This lectureship provides a unique opportunity for chemists in the early stages of their careers and we would like to congratulate Dr. Stewart for his achievement in winning this award. We are pleased that this award grants scientists the recognition they deserve.
Reaxys is a unique web-based chemistry database combining reaction and substance data in organic, organometallic, inorganic and physical chemistry with synthesis planning. Reaxys allows researchers to get the information they need in a single overview, from source publications carefully selected for their importance and relevance to research chemists.
About Elsevier Properties SA
Elsevier Properties SA is a center of excellence within Reed Elsevier for the management of intellectual property. Elsevier Properties SA owns the PharmaPendium, Beilstein and Reaxys databases. Trademarks including Reaxys(R), PharmaPendium(TM), SciVal(R) and The Lancet(R) are owned and protected by Elsevier Properties SA and used under license. For additional information see http://www.reedelsevier.com .
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet (http://www.thelancet.com) and Cell (http://www.cell.com), and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect (http://www.sciencedirect.com), Scopus (http://www.scopus.com), Reaxys (http://www.reaxys.com), MD Consult (http://www.mdconsult.com) and Nursing Consult (http://www.nursingconsult.com), which enhance the productivity of science and health professionals, and the SciVal suite (http://www.scival.com) and MEDai's Pinpoint Review (http://www.medai.com), which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier (http://www.elsevier.com) employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC (http://www.reedelsevier.com), a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Media Contact: Tom Reller Elsevier +1-215-239-3508 T.Reller@elsevier.com
CONTACT: Media Contact: Tom Reller, Elsevier, +1-215-239-3508,T.Reller@elsevier.com .